Drug profile · INN
mepolizumab
NUCALA
mepolizumab (NUCALA) is a interleukin-5 inhibitor. Associated with GlaxoSmithKline. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — mepolizumab
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
mepolizumab (NUCALA) is a interleukin-5 inhibitor. Associated with GlaxoSmithKline. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-5 inhibitor
Primary target: Interleukin-5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mepolizumab?
mepolizumab (NUCALA) is a interleukin-5 inhibitor. Associated with GlaxoSmithKline. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for mepolizumab?
NUCALA is a marketed brand name for mepolizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mepolizumab?
mepolizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.